Want to add more growth to your portfolio but not sure where to look? Companies such as Starpharma Holdings and Perseus Mining are deemed high-growth by the market, with a positive outlook in all areas – returns, profitability and cash flows. Analysing the most recent financial data, I’ve created a list of companies that compare favourably in all criteria, making them potentially good additions to your portfolio.
Starpharma Holdings Limited (ASX:SPL)
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia and Canada. Starpharma Holdings was formed in 1996 and with the market cap of AUD A$524.31M, it falls under the small-cap category.
SPL’s forecasted bottom line growth is an exceptional 99.66% over the next few years, increasing from the existing net income level of $-15.22M. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 26.37%. SPL’s bullish prospects on its profitability make it an interesting stock to invest more time to understand how it can add value to your portfolio. Should you add SPL to your portfolio? I recommend researching its fundamentals here.
Perseus Mining Limited (ASX:PRU)
Perseus Mining Limited engages in the exploration, evaluation, development, and mining of gold properties in West Africa. Started in 2003, and currently run by Jeffrey Quartermaine, the company provides employment to 464 people and with the stock’s market cap sitting at AUD A$428.81M, it comes under the small-cap category.
PRU is expected to deliver an extremely high earnings growth over the next couple of years of 65.14%, bolstered by an equally impressive revenue growth of 99.07%. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a positive return on equity of 4.53%. PRU’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Want to know more about PRU? Check out its fundamental factors here.
Anatara Lifesciences Ltd (ASX:ANR)
Anatara Lifesciences Limited engages in the development of non-antibiotic oral solutions for gastro intestinal diseases in animals and humans in Australia. Anatara Lifesciences is currently led by CEO Melvyn Bridges. It currently has a market cap of AUD A$85.73M placing it in the small-cap category